Glucagon analogues

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8642541
APP PUB NO 20110293587A1
SERIAL NO

13139678

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ZEALAND PHARMA A/SSMEDELAND 36 GLOSTRUP DK-2600

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Daugaard, Jens Rosengren Virum, DK 12 458
Larsen, Bjarne Due Roskilde, DK 69 1486
Meier, Eddi Vaerløse, DK 22 755
Neerup, Trine Skovlund Ryge Frederikssund, DK 7 181
Riber, Ditte Frederiksberg, DK 48 1015
Skovgaard, Marie København Ø, DK 13 480

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 4, 2025
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00